QUILT-2.023: A PHASE 3, OPEN-LABEL, 3-COHORT RANDOMIZED STUDY OF N-803 IN COMBINATION WITH CURRENT STANDARD OF CARE VS STANDARD OF CARE AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Lung cancer begins in the lungs and most often occurs in people who smoke. While this is a very simple statement to make, living with the FACT of lung cancer is not so simple. If you or a loved one has been diagnosed with lung cancer the Gettysburg Cancer Center is here to help.
There are many different types of effective therapies available for the treatment of lung cancer. But are these therapies enough? Do they work as well as you want? Is there something new? Something better? The Gettysburg Cancer Center endeavors to answer these questions by bringing new and innovative treatments here, close to home in the form of clinical research. One such opportunity comes from a pharmaceutical company called ImmunityBio, Inc.
The QUILT 2.023 study uses various immunotherapies in combination with a new drug called N-803. This study is for the treatment of advanced or metastatic lung cancer. Immunotherapies are an effective and well tolerated treatment for lung cancer. N-803 is a new type of immunotherapy that is showing very promising results so far.
If you are interested in more information on this study, please contact us. Refer to the QUILT 2.023 study. You can also find information on this study by going to clinicaltrials.gov website and searching for NCT03520686.